Managing mRNA Instability
Publication
Article
Pharmaceutical TechnologyThe Real Message Behind Commercial mRNA Products, April 2023 eBook
Volume 2023 eBook
Issue 3
Pages: 50–52
Unique solutions are required to protect inherently unstable messenger RNA.
Paulista - Stock.adobe.com
Oligonucleotide drug substances generally are unstable at room temperature, and some are also degraded in the presence of certain enzymes. That is why, in part, they are formulated using special delivery solutions such as lipid nanoparticles (LNPs). (These delivery technologies also facilitate entry of nucleotide APIs into target cells.) Degradation can occur via loss of terminal nucleotides or certain functional groups, oxidation, and other mechanisms. Oligonucleotide–oligonucleotide interactions that can occur at higher concentrations are an added concern. These instability issues must be managed throughout the entire manufacturing process.
The challenges are particularly great for messenger RNA (mRNA), which can be degraded by enzymes found commonly in the environment, temperature, and due to the overall shear sensitivity of the
long-chained molecule.
Read this article in Pharmaceutical Technology’s The Real Message Behind Commercial mRNA Products eBook.
Editor’s Note: This article was previously published in Pharmaceutical Technology 2022 46 (12).
About the author
Cynthia A. Challener, PhD, is a contributing editor to Pharmaceutical Technology®.
Article details
Pharmaceutical Technology
eBook: The Real Message Behind Commercial mRNA Products
April 2023
Pages: 50–52
Citation
When referring to this article, please cite it as Challener, C. A. Managing mRNA Instability During Formulation, Manufacturing, and Shipment. Pharmaceutical Technology's The Real Message Behind Commercial mRNA Products eBook (April 2023).
Articles in this issue
Stability in mRNA-LNP Formulations
Nucleic Acid-based Therapeutics Are Stepping into the Spotlight
Learning to Think at Lightspeed
Managing mRNA Instability
The Role of Separation Techniques in the Analysis of mRNA Therapeutic Drug Substances and Drug Products
The Marriage of RNA and Mass Spectrometry
Delivering on the Potential of mRNA Therapeutics
The COVID-19 Pandemic and Its Positive Impact on RNA Drug Development
Recent Videos
Related Content
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024Podcast
In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024Podcast
In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
